Focal Segmental Glomerulosclerosis Market
Focal Segmental Glomerulosclerosis Market Size, Share & Industry Analysis, By Disease Type (Primary FSGS, Secondary FSGS), By Treatment Type (Corticosteroids, Immunosuppressants, ACE Inhibitors/ARBs, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The Focal Segmental Glomerulosclerosis (FSGS) Market is projected to grow at a CAGR of 6.8% from 2024 to 2031. The market value is expected to increase from USD XX billion in 2024 to USD YY billion by 2031.
North America currently dominates the market, accounting for the largest share of global revenue. Key metrics include increasing prevalence of FSGS, advancements in diagnostic technologies, and rising investments in research and development for novel therapies. The market is experiencing steady growth driven by the rising incidence of FSGS, particularly in developed countries, coupled with the growing awareness about rare kidney disorders. Technological advancements in renal pathology and the emergence of targeted therapies are further propelling market expansion, offering new hope for patients with this challenging condition.
Market Dynamics:
Market Trend: Shift towards personalized medicine approaches in FSGS treatment
A significant trend in the Focal Segmental Glomerulosclerosis market is the increasing focus on personalized medicine approaches. This shift is driven by the heterogeneous nature of FSGS and the variable response to standard treatments among patients. Researchers and pharmaceutical companies are increasingly exploring genetic and molecular markers that can predict treatment responses and guide therapeutic decisions. For instance, recent studies have identified specific genetic mutations associated with steroid-resistant FSGS, leading to the development of targeted therapies. This trend is particularly evident in clinical trial designs, where patient stratification based on genetic profiles is becoming more common. The adoption of precision medicine in FSGS management is expected to improve treatment outcomes and reduce the risk of unnecessary side effects from ineffective therapies. As more biomarkers are validated and incorporated into clinical practice, we can expect to see a more tailored approach to FSGS treatment, potentially revolutionizing patient care in the coming years.
Market Driver: Increasing prevalence of FSGS and associated risk factors
The rising incidence of focal segmental glomerulosclerosis is a significant driver for the market. While FSGS is considered a rare disease, its prevalence has been increasing globally, particularly in developed countries. According to the National Kidney Foundation, FSGS accounts for approximately 40% of nephrotic syndrome cases in adults. The increasing prevalence can be attributed to various factors, including the rising rates of obesity, diabetes, and hypertension, which are known risk factors for secondary FSGS. For instance, a study published in the Journal of the American Society of Nephrology reported that the incidence of FSGS increased by 13-fold over the past two decades in the United States. Additionally, improved diagnostic techniques have led to better detection rates, contributing to the apparent increase in prevalence. The growing patient pool provides a strong impetus for pharmaceutical companies to invest in research and development of new therapies, driving market growth. Moreover, the high unmet medical need in FSGS, particularly in steroid-resistant cases, further fuels the demand for innovative treatments.
Market Restraint: High cost of treatment and limited therapeutic options
The high cost of treatment for focal segmental glomerulosclerosis poses a significant challenge to market growth, particularly in developing regions. FSGS often requires long-term management with expensive immunosuppressive drugs, and in many cases, patients may need renal replacement therapy or kidney transplantation. For instance, the annual cost of treatment for a patient with FSGS can exceed $50,000 in the United States, not including potential hospitalization costs. This financial burden can lead to treatment non-adherence and reduced access to care, especially in regions with limited healthcare resources or inadequate insurance coverage. Furthermore, the limited number of FDA-approved therapies specifically for FSGS constrains treatment options. The current standard of care, which primarily relies on off-label use of immunosuppressants, may not be effective for all patients, particularly those with steroid-resistant FSGS.
This lack of targeted therapies not only impacts patient outcomes but also limits market growth potential. The high failure rate in clinical trials for FSGS treatments further compounds this issue, discouraging some pharmaceutical companies from investing in this challenging therapeutic area.
Segment Overview:
Immunosuppressants dominate the treatment segment, driven by their efficacy in managing both primary and secondary FSGS.
Immunosuppressants currently hold the largest market share in the Focal Segmental Glomerulosclerosis treatment segment. This dominance can be attributed to their established efficacy in managing both primary and secondary FSGS, particularly in cases that are resistant to corticosteroid therapy. These drugs, which include calcineurin inhibitors (such as cyclosporine and tacrolimus) and mycophenolate mofetil, have shown significant success in inducing remission and preserving renal function in FSGS patients.
The popularity of immunosuppressants is further bolstered by recent clinical evidence supporting their use. For instance, a meta-analysis published in the Clinical Journal of The The American Society of Nephrology found that calcineurin inhibitors were associated with a higher rate of complete or partial remission compared to other therapies in adults with steroid-resistant FSGS. Specifically, the study reported a remission rate of 60% with calcineurin inhibitors, compared to 40% with other treatments.
Moreover, the expanding applications of immunosuppressants beyond first-line therapy are contributing to their market dominance. These drugs are increasingly being used in combination therapies and as maintenance treatments to prevent relapse. A retrospective study published in Kidney International Reports demonstrated that a combination of low-dose prednisone and mycophenolate mofetil was effective in maintaining remission in 70% of FSGS patients over a 5-year follow-up period.
Regional Outlook:
North America leads the Focal Segmental Glomerulosclerosis market, driven by advanced healthcare infrastructure and high investment in rare disease research.
North America, particularly the United States, dominates the global Focal Segmental Glomerulosclerosis market. This regional leadership is attributed to several factors, including a well-established healthcare system, high healthcare expenditure, and significant investment in rare disease research and development.
The prevalence of FSGS in North America has been a significant driver for market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases, FSGS is one of the most common causes of primary nephrotic syndrome in adults in the United States. The region's large patient pool, coupled with greater awareness and better diagnostic capabilities, has created a favorable environment for FSGS treatments.
Recent regulatory initiatives have further bolstered the market in North America. For instance, the FDA's orphan drug designations for several potential FSGS treatments have incentivised pharmaceutical companies to invest in this area. These designations not only provide market exclusivity but also offer tax credits and waived FDA fees, encouraging innovation in this challenging therapeutic space.
North America accounted for approximately YY% of the global Focal Segmental Glomerulosclerosis market in 2023. The United States, in particular, held the largest share within the region, with a market value exceeding $300 million. The region's market is expected to maintain its dominant position throughout the forecast period, driven by ongoing clinical trials for novel therapies and increasing collaborations between academic institutions and pharmaceutical companies focused on FSGS research.
Competitive Intelligence:
The focal segmental glomerulosclerosis market is characterized by a mix of established pharmaceutical companies and emerging biotech firms focused on rare kidney diseases. Key players such as Retrophin, Inc. (now Traverse Therapeutics), Novartis AG, and Pfizer Inc. hold significant market shares due to their ongoing clinical trials and marketed products for FSGS and related conditions.
Travere Therapeutics (formerly Retrophin) has been a frontrunner in the FSGS market with its drug candidate sparsentan. The company's focus on rare nephropathies has positioned it as a key player in the FSGS space. Travere reported promising Phase 3 results for sparsentan in FSGS patients in 2023, potentially paving the way for a new treatment option in the coming years.
Novartis AG has also been active in the FSGS market, particularly with its drug iptacopan, which received FDA Breakthrough Therapy designation for C3 glomerulopathy in 2021. While primarily developed for other rare kidney diseases, iptacopan is being investigated for its potential in FSGS, showcasing the company's commitment to addressing unmet needs in rare nephropathies.
Pfizer Inc., through its rare disease portfolio, has shown interest in the FSGS market. The company's experience in developing treatments for rare diseases and its robust R&D capabilities make it a significant player to watch in the FSGS space.
Emerging players like Goldfinch Bio (acquired by AstraZeneca in 2023) and Apellis Pharmaceuticals are gaining attention through their innovative approaches to FSGS treatment. Goldfinch Bio's precision medicine approach, focusing on genetically defined patient subgroups, represents a new paradigm in FSGS drug development.
The market has also witnessed increased collaboration between pharmaceutical companies and academic institutions. For instance, the NephCure Kidney International-Kidney Health Initiative Focal Segmental Glomerulosclerosis Clinical Endpoint Study is a multi-stakeholder initiative aimed at validating endpoints for FSGS clinical trials, potentially accelerating drug development in this field.
Analyst Opinion:
The Focal Segmental Glomerulosclerosis market is at a critical juncture, with several promising therapies in late-stage clinical development. The shift towards personalized medicine and targeted therapies represents a significant opportunity to improve treatment outcomes for FSGS patients. However, the market faces challenges in terms of clinical trial design and patient recruitment due to the rare nature of the disease and its heterogeneous presentation.
The potential approval of new therapies, such as sparsentan, in the coming years could significantly reshape the treatment landscape for FSGS. However, market success will depend not only on clinical efficacy but also on addressing the high cost of treatment, which remains a significant barrier to access.
An exclusive trend to watch is the integration of artificial intelligence and machine learning in FSGS research and drug development. These technologies could potentially accelerate biomarker discovery and patient stratification, leading to more efficient clinical trials and personalized treatment approaches.
Major Players:
-
Travere Therapeutics, Inc.
-
Novartis AG
-
Pfizer Inc.
-
GlaxoSmithKline plc
-
Apellis Pharmaceuticals, Inc.
-
AstraZeneca plc
-
Boehringer Ingelheim International GmbH
-
ChemoCentryx, Inc. (acquired by Amgen)
-
Complexa Inc.
-
Retrophin, Inc.
Key Developments:
-
September 2023: Travere Therapeutics announced positive topline results from its Phase 3 DUPLEX Study of sparsentan in FSGS, meeting its pre-specified interim proteinuria endpoint.
-
March 2024: AstraZeneca completed the acquisition of Goldfinch Bio, strengthening its position in precision medicine approaches for kidney diseases, including FSGS.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmark—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Travere Therapeutics, Inc.
5.2. Novartis AG
5.3. Pfizer Inc.
5.4. GlaxoSmithKline plc
5.5. Apellis Pharmaceuticals, Inc.
5.6. AstraZeneca plc
5.7. Boehringer Ingelheim International GmbH
5.8. ChemoCentryx, Inc. (acquired by Amgen)
5.9. Complexa Inc.
5.10. Retrophin, Inc. (LIST, NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards personalised medicine approaches in FSGS treatment
6.1.2. Integration of AI and machine learning in FSGS research
6.1.3. Increasing focus on combination therapies for FSGS
6.2. Market Drivers
6.2.1. Increasing prevalence of FSGS and associated risk factors
6.2.2. Advancements in diagnostic technologies for kidney diseases
6.2.3. Rising investments in rare disease research and development
6.3. Market Restraints
6.3.1. High cost of treatment and limited therapeutic options
6.3.2. Challenges in clinical trial design and patient recruitment
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DISEASE TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Primary FSGS
7.1.1. Tip Variant
7.1.2. Cellular Variant
7.1.3. Collapsing Variant
7.1.4. Others
7.2. Secondary FSGS
7.2.1. Obesity-related FSGS
7.2.2. Drug-induced FSGS
7.2.3. Virus-associated FSGS
7.2.4. Others
8. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Corticosteroids
8.2. Immunosuppressants
8.2.1. Calcineurin Inhibitors
8.2.2. Mycophenolate Mofetil
8.2.3. Others
8.3. ACE Inhibitors/ARBs
8.4. Others
9. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Oral
9.2. Intravenous
10. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online pharmacies
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH)--2020-2031.
Focal Segmental Glomerulosclerosis Market Segmentation:
By Disease Type:
-
Primary FSGS
-
Secondary FSGS
By Treatment Type:
-
Corticosteroids
-
Immunosuppressants
-
ACE Inhibitors/ARBs
-
Others
By Route of Administration:
-
Oral
-
Intravenous
By Distribution Channel:
-
Hospital Pharmacies
-
Retail pharmacies
-
Online pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511